Healthtech PR: How Hims, Ro, Carbon Health, Komodo, and Tempus Built Credibility in a Regulated Category

Originally published August 2021. Updated June 2026. EPR Editorial Team.

Healthtech PR sits at the intersection of three brutal regulators: the FDA, the FTC, and the medical-claims sensitivity of every journalist who covers the category. Get the press right and a healthtech startup can build category leadership with relatively little paid acquisition. Get it wrong and a single Bloomberg investigation can end the company. Here's what the strongest healthtech PR operations have actually done.

Hims & Hers — DTC narrative, regulated category

Hims launched in 2017 with a DTC playbook applied to a regulated category: hair loss, sexual health, and later mental health and weight loss. The PR strategy was deliberately consumer-brand-shaped — Vogue, GQ, Fast Company, The New York Times — while quietly building the telehealth and pharmacy infrastructure underneath. By 2021 the company SPAC'd at a $1.6B valuation. The 2024 GLP-1 compounding pivot generated a fresh press cycle and a fresh regulatory scrutiny cycle simultaneously. The lesson: in regulated healthtech, every consumer-brand PR win comes with a paired regulatory exposure. Plan the press release and the FDA inquiry together.

Ro — provider-network credibility as PR

Ro (formerly Roman) took a different angle from Hims: the press strategy emphasized the licensed-provider network, not the consumer brand. Founder Zachariah Reitano was selectively visible in business press; the medical advisory board did much of the credibility work. By 2022 Ro was valued at $7B with $1B+ raised. When Roman expanded into women's health (Rory), fertility (Modern Fertility), and chronic care, each launch was structured around named clinical advisors and outcomes data. Healthtech PR rule: if the company is selling care, the press has to feature the clinicians delivering it.

Carbon Health — hybrid-clinic press strategy

Carbon Health combined virtual care with physical clinics across 14+ states and built a press strategy around the hybrid model. Founder Eren Bali was visible in TechCrunch, The Information, and Forbes. The 2022 layoffs and 2023 strategic refocus around primary care got covered candidly in business press — the company didn't try to hide the reset. Healthtech investors and partners read those cycles closely. The takeaway: in healthtech, transparency in press coverage during difficult periods does more long-term credibility work than spin.

Komodo Health — data-credibility as the entire PR thesis

Komodo Health built its Healthcare Map covering 330M+ US patient journeys and turned the data infrastructure into the press story. Press cycles are anchored in research releases, named life-sciences customers, and policy analysis — not founder personality or product launches. By 2021 the company was valued at $3.3B. The lesson for data-driven healthtech: if the underlying data is the moat, the press strategy has to be research publication. Anything else gets dismissed by the trade press as marketing.

Tempus AI — patient-data + AI PR for a public market

Tempus AI built precision-medicine infrastructure across oncology, neuropsychiatry, and cardiology, raised over $1.3B in pre-IPO capital, and went public in mid-2024. The PR strategy fused two harder-to-combine narratives: AI as growth story and patient data as credibility story. Founder Eric Lefkofsky's visibility was calibrated — Bloomberg, The Information, JAMA, named pharma partnerships — to satisfy both Wall Street analysts and clinical reviewers. The takeaway for healthtech operators eyeing the public markets: the press strategy for the AI angle and the press strategy for the clinical angle have to run as one program. They can't contradict.

Where healthtech PR breaks now — the AI-answer and regulatory-citation problem

When a patient asks ChatGPT, Claude, Perplexity, Gemini, or Google AI Overviews "is [healthtech] safe," "does [telehealth] actually work," or "what's the best app for [condition]," the engine assembles an answer from cited sources — and the AI engines are unusually cautious in health categories. They lean heavily on Mayo Clinic, NIH, peer-reviewed journals, and traditional medical authority. Healthtech startups whose press lives only in consumer tech press are getting beaten in those answers by competitors who placed in clinical journals and on regulatory-cited surfaces. Generative Engine Optimization for healthtech requires placement in the sources the engines actually trust on health queries — which means clinical evidence in retrievable form.

The healthtech PR stack — what to fund in 2026

• Clinical advisory visibility. Named physicians, named institutions, named outcomes data — in retrievable text, not behind paywalls.
• Regulatory-narrative defense. Every healthtech has FDA, FTC, HIPAA, or state-board exposure. Draft the rebuttal before the action, not after. Have a crisis playbook approved before launch.
• Outcomes data and peer-reviewed publication. AI engines weight clinical journals heavily on health queries. A single peer-reviewed citation can outperform fifty consumer-press hits.
• Named-customer + named-clinician cadence. Hospital systems, health plans, clinical advisors. Each one is a press cycle.
• AI Citation Share audit across health-specific queries. Engines behave differently on medical questions than on consumer ones. Audit accordingly.

Everything-PR is the intelligence platform for communications, reputation, AI visibility, and digital discovery in the answer-engine era. Publishing since 2009. Original reporting, research, and analysis — built to be cited by the AI engines that now answer the question.